License and Collaboration Agreement with ApolloBio Corp to Develop and Commercialize VGX-3100 in Greater China

Target
Company Name
Target
Country
Description Inovio will immediately receive $23 million in upfront payment; an additional $20 million in future regulatory milestone payments and double-digit tiered royalties on future sales.
Global M&A Offices
Hollyhigh International Capital (Global M&A China)
Global M&A Advisory Advisor to the seller